Condition
Ossification, Heterotopic
Total Trials
3
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
100%
1 of 1 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
2Total
Not Applicable (1)
P 4 (1)
Trial Status
Unknown2
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT04049461Unknown
Heterotopic Ossification in Abdominal Incision and Pancreatic Cancer
NCT01022190Phase 4CompletedPrimary
Prevention of Heterotopic Ossification With Arcoxia After Total Hip Replacement
NCT01631669Not ApplicableUnknownPrimary
Celecoxib for Primary Prophylaxis of Combat-Related Heterotopic Ossification
Showing all 3 trials